Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Antibody-based immunotherapy is a promising strategy for targeting chemoresistant leukemic cells. However, classical antibody-based approaches are restricted to targeting lineage-specific cell surface antigens. By targeting intracellular antigens, a large number of other leukemia-associated targets would become accessible. In this study, we evaluated a novel T-cell bispecific (TCB) antibody, generated by using CrossMAb and knob-into-holes technology, containing a bivalent T-cell receptor–like binding domain that recognizes the RMFPNAPYL peptide derived from the intracellular tumor antigen Wilms tumor protein (WT1) in the context of HLA-A*02. Binding to CD3ε recruits T cells irrespective of their T-cell receptor specificity. WT1-TCB elicited antibody-mediated T-cell cytotoxicity against AML cell lines in a WT1- and HLA-restricted manner. Specific lysis of primary acute myeloid leukemia (AML) cells was mediated in ex vivo long-term cocultures by using allogeneic (mean ± standard error of the mean [SEM] specific lysis, 67 ± 6% after 13-14 days; n = 18) or autologous, patient-derived T cells (mean ± SEM specific lysis, 54 ± 12% after 11-14 days; n = 8). WT1-TCB–treated T cells exhibited higher cytotoxicity against primary AML cells than an HLA-A*02 RMF-specific T-cell clone. Combining WT1-TCB with the immunomodulatory drug lenalidomide further enhanced antibody-mediated T-cell cytotoxicity against primary AML cells (mean ± SEM specific lysis on days 3-4, 45.4 ± 9.0% vs 70.8 ± 8.3%; P = .015; n = 9-10). In vivo, WT1-TCB–treated humanized mice bearing SKM-1 tumors exhibited a significant and dose-dependent reduction in tumor growth. In summary, we show that WT1-TCB facilitates potent in vitro, ex vivo, and in vivo killing of AML cell lines and primary AML cells; these results led to the initiation of a phase 1 trial in patients with relapsed/refractory AML (#NCT04580121).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Schlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umaña, P., & Mössner, E. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw040 · Cited by 425
Self-citationVan Tendeloo, V. F., Van de Velde, A., Van Driessche, A., Cools, N., Anguille, S., Ladell, K., Gostick, E., Vermeulen, K., Pieters, K., Nijs, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008051107 · Cited by 377 · cited 1×
“In a phase 2 clinical trial for postremission therapy of AML, vaccination with dendritic cells electroporated with WT1 messenger RNA (mRNA) was shown to reduce the risk of relapse after standard chemotherapy.(30,31) Various WT1 peptide vaccines have been tested in phase 1 and phase 2 clinical trials.”
BackgroundAnguille, S., Van de Velde, A. L., Smits, E. L., Van Tendeloo, V. F., Juliusson, G., Cools, N., Nijs, G., Stein, B., Lion, E., Van Driessche, A., et al. (2017) · Blood · doi:10.1182/blood-2017-04-780155 · Cited by 230
Cited by
The present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 490
Self-citationImmune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies
Kroll, K. T., Mata, M. M., Homan, K. A., Micallef, V., Carpy, A., Hiratsuka, K., Morizane, R., Moisan, A., Gubler, M., Walz, A.-C., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305322120 · Cited by 79
Leclercq-Cohen, G., Steinhoff, N., Albertí Servera, L., Nassiri, S., Danilin, S., Piccione, E., Yángüez, E., Hüsser, T., Herter, S., Schmeing, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3667 · Cited by 65
Self-citationMahoney, K. E., Reser, L., Ruiz Cuevas, M. V., Abelin, J. G., Shabanowitz, J., Hunt, D. F., & Malaker, S. A. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.100971 · Cited by 9
Metadata
- Authors
- Augsberger, C., Hänel, G., Xu, W., Pulko, V., Hanisch, L. J., Augustin, A., Challier, J., Hunt, K., Vick, B., Rovatti, P. E., Krupka, C., Rothe, M., Schönle, A., Sam, J., Lezan, E., Ducret, A., Ortiz-Franyuti, D., Walz, A.-C., Benz, J., Bujotzek, A., Lichtenegger, F. S., Gassner, C., Carpy, A., Lyamichev, V., Patel, J., Konstandin, N., Tunger, A., Schmitz, M., von Bergwelt-Baildon, M., Spiekermann, K., Vago, L., Jeremias, I., Marrer-Berger, E., Umaña, P., Klein, C., & Subklewe, M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-12-23
- Volume
- 138
- Issue
- 25
- Pages
- 2655-2669
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3184041689
- Cited by
- 69
- References
- 5
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. https://app.cochat.ai/papers/10.1182/blood.2020010477
- The paper
- Augsberger, C., Hänel, G., Xu, W., Pulko, V., Hanisch, L. J., Augustin, A., Challier, J., Hunt, K., Vick, B., Rovatti, P. E., Krupka, C., Rothe, M., Schönle, A., Sam, J., Lezan, E., Ducret, A., Ortiz-Franyuti, D., Walz, A.-C., Benz, J., . . . Subklewe, M. (2021). Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood. https://doi.org/10.1182/blood.2020010477
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.